Jane Wu

33 papers receiving 1.3k citations

Jane Wu's Hit Papers

Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors 2020 · 313 citations
3130+2+4Years since publication100200300

Peers

Jane Wu
Comparison fields: 5 of 94
  • Obstetrics and Gynecology 181
  • Oncology 409
  • Reproductive Medicine 99
  • Cancer Research 131
  • Infectious Diseases 164
Replace Kohei Fujita with:
Kohei Fujita Japan
André D’Hoore Belgium
Hugh Mostafid United Kingdom
Antonis Valachis Sweden
Thomas Seisen France
Alexandra Stewart United Kingdom
Lee Wu United States
Clyde D. Ford United States
Wiking Månsson Sweden
Michael McHale United States
Jane Wu relative to Kohei Fujita Japan Kohei Fujita's profile →
Citations per field
00.5×4.2×
Kohei Fujita · 1×
Citations per year

Countries citing papers authored by Jane Wu

Since Specialization
Citations

This map shows the geographic impact of Jane Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jane Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jane Wu more than expected).

Fields of papers citing papers by Jane Wu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jane Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jane Wu. The network helps show where Jane Wu may publish in the future.

Co-authors

The 25 scholars most cited alongside Jane Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jane Wu Line = papers co-authored together Jane Wu links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
Hit paper breakdown →
2020366
2
Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
Hit paper breakdown →
2020313
3 2009107
4 199796
5 199769
6 199847
7 199746
8 200140
9 200537
10 202031
11 200426
12 201719
13 199516
14 201012
15 20059
16 20198
17 20248
18 20156
19 20196
20 20166

About Jane Wu

Jane Wu is a scholar working on Oncology, Infectious Diseases, Pulmonary and Respiratory Medicine, Public Health, Environmental and Occupational Health and Emergency Medicine, having authored 33 papers that have together received 1.3k indexed citations. Recurring topics across this work include Antifungal resistance and susceptibility (4 papers), Renal cell carcinoma treatment (3 papers), Intensive Care Unit Cognitive Disorders (3 papers), Chronic Lymphocytic Leukemia Research (3 papers), Trauma and Emergency Care Studies (3 papers), Cancer Immunotherapy and Biomarkers (2 papers), HIV/AIDS oral health manifestations (2 papers) and Endometrial and Cervical Cancer Treatments (2 papers). The work is most often cited by research in Obstetrics and Gynecology (181 citations), Oncology (409 citations), Reproductive Medicine (99 citations), Cancer Research (131 citations) and Infectious Diseases (164 citations). Jane Wu has collaborated with scholars based in United States, Australia and United Kingdom. Frequent co-authors include Corina E. Dutcus, Matthew H. Taylor, Daniel E. Stepan, Vicky Makker, Robert Shumaker, Robert J. Motzer, Chung‐Han Lee, Drew Rasco, Mark A. Klausner and David G. Lange. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Annals of Allergy Asthma & Immunology, The Journal of Clinical Pharmacology and Clinical Rehabilitation.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact